Clinical Research Directory
Browse clinical research sites, groups, and studies.
WATCHMAN FLX Pro European Registry
Sponsor: Boston Scientific Corporation
Summary
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2025-12-17
Completion Date
2028-09
Last Updated
2026-04-09
Healthy Volunteers
No
Interventions
Left atrial appendage closure
The WATCHMAN FLX Pro LAAC Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in adult patients with non-valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anticoagulation therapy. The VersaCross Connect™ LAAC Access Solution is indicated for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture.
Locations (7)
Rigshospitalet Copenhagen
Copenhagen, Denmark
Kath Krankenhaus St Johann Nepomuk
Erfurt, Germany
Asklepios Klinik Saint Georg
Hamburg, Germany
Asklepios Klinik Nord Heidberg
Hamburg, Germany
Hospital de Leon
León, Spain
Clinica Universidad de Navarra
Pamplona, Spain
University Hospital Basel
Basel, Switzerland